B. Michael Silber, Ph.D., Scientific Advisor
Dr. B. Michael Silber is a professor of Neurology, Bioengineering and Therapeutic Sciences, and Chief of Drug Discovery R& D at Institute for Neurodegenerative Diseases (IND) University of California School of Medicine.
Prior to joining the faculty at UCSF and the IND, Dr. Silber held senior executive R & D operating positions at leading pharmaceutical, biotechnology, or biopharmaceutical companies, including Roche, Johnson & Johnson, Pfizer, Cetus, and Lederle. He has contributed to the discovery, development, or regulatory approval of 23 medicines across a wide range of diseases.
Dr. Silber has over 170 research articles, book chapters, abstracts, and invited presentations at national and international meetings. He is a reviewing editor or reviewer for many national or international scientific journals. He is a principal or co-principal investigator on NIH funded program project grants, foundation and donor sponsored research being conducted at the IND. He was elected and serves on the UC Berkeley Bioengineering Council, was on the Keystone Symposia SAB for nine years, is a study-section reviewer for the NIH, and was formerly on the University of Washington School of Pharmacy Corporate Board. He is also a Board member of several biotechnology or life-sciences startup companies, and is a Senior Strategic and Scientific Advisor to life sciences, biotechnology, and VC companies focused on discovering new drug and drug-device combinations. He has made many contributions to scientific research and technology in drug discovery R & D.
Dr. Silber received his Doctor of Pharmacy degree from University of Southern California and his Ph.D. in Pharmaceutical Chemistry and Pharmacology from University of California, San Francisco.